Chevron’s Fall Strengthens Industry’s Hand In Disagreements With US FDA, But May Spur Delays

Firms can be more forceful in disputes with FDA now that Supreme Court has eliminated Chevron deference. Questions around whether an evidentiary standard has been met may be ripe for challenge, legal experts said, but they also caution that sponsors will face more uncertainty.

Produce
What types of FDA disputes are ripe for litigation in a post-Chevron world? • Source: Shutterstock

Biopharma companies that have a prelitigation dispute with the US Food and Drug Administration will be in a stronger position to argue their views before the agency now that the US Supreme Court has overturned the Chevron doctrine of deference.

Key Takeaways

  • Sponsors can take a more forceful position with the FDA in prelitigation disputes now that agency decisions are not afforded Chevron deference by courts.

However, the FDA is likely to take much longer to make decisions on regulatory and legal questions. The agency will...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet